BTK and B-cell chronic lymphocytic leukemia: Bruton tyrosine kinase inhibitors (BTKis) are a key class of targeted therapies for B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).